PALISADE CAPITAL MANAGEMENT, LP - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAD4. A total of 45 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
PALISADE CAPITAL MANAGEMENT, LP ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$1,138,650
+23.4%
1,500,0000.0%0.03%
+28.0%
Q2 2023$922,573
-3.5%
1,500,0000.0%0.02%
-3.8%
Q1 2023$956,261
-17.2%
1,500,000
-50.0%
0.03%
-16.1%
Q4 2022$1,155,000
-13.2%
3,000,0000.0%0.03%
-18.4%
Q3 2022$1,331,000
+5.4%
3,000,0000.0%0.04%
+11.8%
Q2 2022$1,263,000
-11.6%
3,000,0000.0%0.03%
+3.0%
Q1 2022$1,429,0003,000,0000.03%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Diameter Capital Partners LP 71,757,000$44,221,6864.15%
Context Capital Management, LLC 33,683$20,8461.88%
INHERENT GROUP, LP 9,000,000$5,587,1731.54%
BRAIDWELL LP 62,294,000$38,552,3281.26%
Aequim Alternative Investments LP 30,000,000$18,566,3120.70%
DeepCurrents Investment Group LLC 22,355,000$13,838,3720.55%
ABSOLUTE INVESTMENT ADVISERS, LLC 5,500,000$3,408,5920.48%
ARISTEIA CAPITAL, L.L.C. 30,280,000$18,739,5980.42%
Weiss Asset Management LP 4,500,000$2,773,2090.21%
Orbimed Advisors 15,000,000$9,265,3500.17%
View complete list of BRIDGEBIO PHARMA INC shareholders